Blood plasma-based biomaterials as an affordable biomedical platform technology-Carnegie Mellon University in Rwanda - Carnegie Mellon University

Blood Plasma-based Biomaterials as an Affordable Biomedical Platform Technology

Monday 29th July 2013


Dr. Phil Campbell
Research Professor, Institute for Complex Engineered Systems, Carnegie Mellon University

Dr. Phil Campbel gave a distinguished lecture on  blood platelets teh fact that they contain an array of growth factors, extracellular matrix molecules and other signaling molecules that are released into the injury site upon platelet activation, thus providing the cues needed to help initiate and orchestrate tissue repair. In an effort to harness this activity for therapeutic use, autologous concentrated platelet-rich plasma (PRP) has become a popular therapy, where the desired outcome is to overcome the body’s limitations to tissue repair and accelerate healing. However, the effectiveness of PRP therapies remains controversial due to variable clinical outcomes. Variability is in part due to PRP preparation issues and the inherent variability in platelet quantity and quality between individuals. Additionally, PRP as currently delivered cannot be spatially contained, is rapidly absorbed, and must be prepared at point and time of use. We have developed solid, bioactive plasma-based biomaterials (PBMs) that begin to overcome these issues. Pooled allogenic plasma (containing entire plasma and platelets) is utilized to reduce PBM lot-to-lot variability and sourcing is readily scalable. PBMs are inexpensive to manufacture, safe, available as off-the shelf products, formable into complex 3D shapes, and biodegradable with tunable biomechanical and degradation properties, while retaining inherent biological activities. PBM manufacture is compatible with the incorporation of a range of drugs including antimicrobials and anesthetics. PBMs represent a platform biomedical technology with a broad variety of clinical applications. Due to their affordability, PBMs have potential in clinical markets where the need is high but cost is a barrier to treatment.

Dr. Phil Campbell is a Research Professor within the Institute for Complex Engineered Systems within CMU’s Carnegie Institute of Technology with appointments in Biomedical Engineering, Biological Sciences, Material Science and Engineering, Molecular Biosensor and Imaging Center, and McGowan Institute for Regenerative Medicine. He has over 25 years experience conducting interdisciplinary biomedical engineering related research encompassing the areas of endocrinology, bioimaging, microimplantable biosensors, bioresorbable electronics, bioprinting-based biological patterning with special interest in musculoskeletal tissue repair and regeneration across the spectrum of in vitro to in vivo. He received his Ph.D. from the Pennsylvania State University in Physiology in 1988. Prior to coming to CMU in 1998 he was 10 years in the Department of Orthopaedics within the Allegheny Health Sciences University System, Allegheny General Hospital, campus where he performed musculoskeletal research with focus on cancer and tissue reconstruction/regeneration, was responsible for basic sciences instruction for Orthopaedic residents and fellows, and worked closely with both biomedical engineers and clinicians. Since coming to CMU he has continued to develop and expand his multidisciplinary research interests to include departments across CMU, as well as collaborative research within and beyond the Pittsburgh region.

Dr. Campbell is actively involved in outreach education from K-12 through to senor adults He is a co-founder of the Pittsburgh regional middle/school teacher tissue engineering intern program. He regularly lectures and conducts hands-on tissue engineering laboratory experiences for such programs as the Pittsburgh Science Festival, the Pittsburgh Tissue Engineering Initiative, the Pennsylvania Governor’s School, the Pittsburgh Jewish Foundation, the Girl Scout Biotechnology Initiative, Academy for Lifelong Learning, and the Elderhausen Program. He has been a regular guest lecturer at Central Catholic High School for over 20 years and has been a regular instructor within the Academy of Lifelong Learning for over 5 years. Dr. Campbell is actively involved in teaching at CMU both in Biomedical Engineering and Biological Sciences, teaching Physiology, Advanced Physiology and Advanced Cell Biology.
Dr. Campbell is also involved in translation of basic research to business and co-founded Carmell Therapeutics along with Dr. Lee Weiss in Robotics and Dr. Burgess, neurosurgeon at Allegheny General Hospital in 2007. He currently serves as CSO.